A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

Clinical Trials, Metastatic Castration Resistant Prostate Cancer (MCRPC)

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT06457919
Phase: PHASE1|PHASE2
Trial Summary: The purpose of this study is to find out whether tinengotinib in combination with abiraterone acetate and prednisone or enzalutamide is a safe treatment that causes few or mild side effects in people – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Memorial Sloan Kettering Cancer Center
Acronym:

Pin It on Pinterest